The DCGI has permitted EUO of both Oxford-AstraZeneca’s Covishield and Bharat Biotech’s Covaxin for immunisation against Covid-19 in India. On January 1, Covishield was recommended for emergency use whereas Covaxin was recommended for restricted use on January 2. Now the final approval remains with the hands of DGGI. On Saturday, selected hospitals across the country conducted an inoculation dry run to understand the best way to administer the vaccine and plug loopholes in logistics and training.
DCGI gives green signal for emergency use to Serum Institute’s Covidshied and Bharat Biotech’s Covaxin
